Regenerative capabilities of cells.
Guided osseous re-modelling process due to scaffold properties.
Excellent integration of newly formed tissue with surrounding tissue.
Clinical Phase II ongoing Q2 2018 with allogenic product.Licensing & co-development agreement with Salvat.
2017: 6 patients treated with Bonecure autologous product and medical discharged as bone consolidation has been achieved.
2018-2019: Bonecure allogenic product clinical trial on-going with 5 patients treated.